Hanna Gerlovin

1.3k citations
29 papers · 782 indexed · h-index 15
Topics
SARS-CoV-2 and COVID-19 Research (4 papers)Osteoarthritis Treatment and Mechanisms (4 papers)Vitamin D Research Studies (3 papers)

In The Last Decade

Hanna Gerlovin

28 papers receiving 772 citations

Peers

Hanna Gerlovin
Comparison fields: 5 of 98
  • Rheumatology 206
  • Surgery 168
  • Infectious Diseases 150
  • Pharmacology 121
  • Oncology 73
Replace Joshua Pink with:
Joshua Pink United Kingdom
Jonothan C. Tierce United States
Yann Nguyen France
Bo Nancy Yu Canada
Stella G. Muthuri United Kingdom
Vikas Suri India
Neri Alejandro Álvarez‐Villalobos Mexico
Ilan Green Israel
Evelien de Schepper Netherlands
Eugene Merzon Israel
Hanna Gerlovin relative to Joshua Pink United Kingdom Joshua Pink's profile →
Citations per field
00.5×
Joshua Pink · 1×
Citations per year

Countries citing papers authored by Hanna Gerlovin

Since Specialization
Citations

This map shows the geographic impact of Hanna Gerlovin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanna Gerlovin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanna Gerlovin more than expected).

Fields of papers citing papers by Hanna Gerlovin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hanna Gerlovin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanna Gerlovin. The network helps show where Hanna Gerlovin may publish in the future.

Co-authorship network of co-authors of Hanna Gerlovin

This figure shows the co-authorship network connecting the top 25 collaborators of Hanna Gerlovin. A scholar is included among the top collaborators of Hanna Gerlovin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hanna Gerlovin. Hanna Gerlovin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 9
2 21
3 12
4 3
5 9
6 20
7 5
8 21
9 150
10 15
11 10
12 20
13 17
14 10
15 22
16 49
17 33
18 23
19 10
20 61

About Hanna Gerlovin

Hanna Gerlovin is a scholar working on Health, Pharmacology and Rheumatology, having authored 29 papers that have together received 782 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (4 papers), Osteoarthritis Treatment and Mechanisms (4 papers) and Vitamin D Research Studies (3 papers). The work is most often cited by research in Rheumatology (206 citations), Health (69 citations) and Infectious Diseases (150 citations). Hanna Gerlovin has collaborated with scholars based in United States, Australia and Israel. Frequent co-authors include Julie R. Palmer, Elena Losina, Joanne M. Jordan, David J. Hunter, William M. Reichmann, Lynn Rosenberg, David Gagnon, Kelly Cho, A. David Paltiel and Brian R. Ferolito. Their work appears in journals such as New England Journal of Medicine, Annals of Internal Medicine and Diabetes Care.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026